Last reviewed · How we verify
NCT05598242
Amniotic Membrane Treatment for Hyposecretory Dry Eye
Phase 3 trial testing Amniotic membrane extract eye drops (AMEED) in Dry Eye Syndromes in 37 participants. Completed in 15 December 2019.
1 September 2019
Quick facts
| Lead sponsor | Hospital Nacional Profesor Alejandro Posadas |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 37 |
| Start date | 1 February 2019 |
| Primary completion | 1 September 2019 |
| Estimated completion | 15 December 2019 |
| Sites | 3 locations across Argentina |
Drugs / interventions tested
- Amniotic membrane extract eye drops (AMEED) — full drug profile →
Conditions studied
- Dry Eye Syndromes — all drugs for Dry Eye Syndromes →
- Sjogren Syndrome With Keratoconjunctivitis — all drugs for Sjogren Syndrome With Keratoconjunctivitis →
Sponsor
Hospital Nacional Profesor Alejandro Posadas
Who can join
21 and older, female only, with Dry Eye Syndromes or Sjogren Syndrome With Keratoconjunctivitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this randomized, active-controlled, parallel-group trial is to evaluate the clinical efficacy of amniotic membrane extract eye drops (AMEED) in reducing signs and symptoms of hyposecretory dry eye Participants will receibed amniotic membrane extract eye drops 6 times daily and was evaluated at baseline day and day 30th. Researchers will compare against autologous serum eye drops effects
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05598242
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dry Eye Syndromes
Currently open trials in the same condition.
- NCT07412860 — Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hy · NA · recruiting
- NCT06913504 — Comparison Of Blue Light Filter Feature and Blue Blocking Lenses in Digital Device Users With Dry Eye Patients · NA · active not recruiting
- NCT06913465 — The Impact of Hypothyroidism on Tear Production and Dry Eye Symptoms: Implications for Optometric Care · active not recruiting
- NCT06831253 — Efficacy of Platelet-Rich Plasma Injection in Dry Eye Syndrome · NA · recruiting
- NCT06220474 — Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD · NA · recruiting
Other Hospital Nacional Profesor Alejandro Posadas trials
Trials by the same sponsor.
- NCT04893928 — Role of Information and Communication Technologies for Health Support in Inflammatory Bowel Diseases: The DAMASCO Trial · unknown
- NCT06727474 — Clinical and Functional Characteristics of Patients Admitted for Severe COVID-19 Pneumonia · completed
- NCT04493268 — HYPONATREMIA IN COVID-19 PATIENTS · completed
- NCT04356625 — Maximum Expiratory Pressure in Induced Cough as a Predictor of Extubation Failure · NA · completed
- NCT03608761 — Comparison Between Rebamipide 2% Versus Autologous Serum · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05598242 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Nacional Profesor Alejandro Posadas
- Last refreshed: 28 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05598242.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing